Pimobendan Production Cost Reports

The report provides a detailed analysis essential for establishing a pimobendan production plant. It encompasses all critical aspects necessary for pimobendan production, including the cost of pimobendan production, pimobendan plant cost, pimobendan production costs, and the overall pimobendan production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a pimobendan production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Pimobendan is a pharmaceutical compound that is mainly used in veterinary medicine. It is primarily utilised in the treatment of heart failure in dogs, especially in cases linked to mitral valve disease and dilated cardiomyopathy. It finds its main application as an oral medication that helps improve heart muscle contraction and supports better blood circulation. It is commonly prescribed for conditions such as congestive heart failure and dilated cardiomyopathy, where the heart struggles to pump blood properly. It is used to reduce symptoms such as coughing, fatigue, and breathing difficulty in affected animals. It works by improving the strength of heart contractions and widening blood vessels, which helps increase blood flow and reduce pressure on the heart. It is often used as part of long-term treatment plans to improve the quality of life and extend survival time in pets with chronic heart conditions. In addition to dogs, it may also be used in certain cases for cats under veterinary supervision. It also plays an important role in modern veterinary cardiology and is included in various therapeutic protocols for managing chronic cardiac conditions in companion animals.

The primary factor that drives the demand for pimobendan is its application as a veterinary cardiac drug to treat heart disease in animals, especially dogs, which supports its market expansion. Its utilisation as a part of long-term heart management programs to improve quality of life and extend survival time in pets also contributes to its demand in the veterinary and animal healthcare industries. Its application as a cardiotonic agent for treating congestive heart failure in dogs significantly promotes its demand in the veterinary cardiology industry. The demand for veterinary care to treat congestive heart failure and dilated cardiomyopathy in dogs to enhance heart muscle contraction for better circulation further supports its market growth. Rising pet ownership, higher spending on animal healthcare, and growing awareness about early diagnosis of heart conditions also contribute to its market demand. Moreover, improvements in formulation technologies, reliable supplier networks, cold chain requirements, and efficient distribution systems significantly impact industrial pimobendan procurement across global markets. Various factors, such as the cost and availability of active pharmaceutical ingredients, compliance with veterinary drug regulations, quality standards, and patent considerations, also influence its global procurement decisions.

Raw Material for Pimobendan Production

According to the pimobendan production plant project report, the major raw materials for pimobendan production include 6-(3,4-diaminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one and sodium bisulfite, and 4-methoxybenzaldehyde.

Production Process of Pimobendan

The extensive pimobendan production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of pimobendan begins with preparing a mixture of 6-(3,4-diaminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one and sodium bisulfite in DMF, which is heated to promote reaction. Once the mixture reaches the required temperature, 4-methoxybenzaldehyde is added slowly under stirring to facilitate condensation and ring formation. After completion of the reaction, the suspension is cooled and filtered to remove insoluble materials. The clear filtrate is then adjusted to a mildly alkaline pH using ammonia while maintaining controlled temperature conditions to support product formation. Then, water is gradually added to induce crystallisation of the product, which is further separated by filtration. The solid is thoroughly washed with water and acetone to remove residual impurities and finally dried under reduced pressure to obtain pimobendan in its stable monohydrate form.

Pimobendan is a benzimidazole-pyridazinone derivative, and it acts as a selective phosphodiesterase III inhibitor with calcium-sensitising properties. It appears as a white to off-white crystalline powder that has limited water solubility but dissolves readily in organic solvents. The molecular formula of the compound is C19H18N4O2, and its molecular mass is 334.38 g/mol. Its density is 1.398 g/cm³, and it exhibits good thermal stability with a melting point of 216 degrees Celsius. The compound decomposes on heating and does not exhibit a defined atmospheric boiling point. The compound is formulated as chewable tablets for veterinary use and should be stored at controlled room temperature away from moisture and light. The compound demonstrates a good safety profile when used appropriately, though accidental human ingestion may cause cardiovascular effects such as increased heart rate and should prompt immediate medical attention. It is recommended to wash hands thoroughly after handling the compound and store it securely to prevent accidental exposure.